Effect of Adjunctive Simvastatin on Depressive Symptoms Among Adults With Treatment-Resistant Depression

Key Points Question Does adjunctive treatment with 20 mg/d of simvastatin lead to an improvement in depressive symptoms in adults with treatment-resistant depression? Findings In this randomized clinical trial of 150 participants with treatment-resistant unipolar depression, 12 weeks of 20 mg/d of simvastatin added to standard care did not show a statistically significant benefit compared with placebo added to standard care on the overall course of depressive symptoms. Meaning In this study, simvastatin was not beneficial for the treatment of symptoms of treatment-resistant depression compared with standard care.

[1]  E. Mayo-Wilson,et al.  Designing clinically useful psychopharmacological trials: challenges and ways forward. , 2022, The lancet. Psychiatry.

[2]  B. Mulsant,et al.  Magnitude of the Placebo Response Across Treatment Modalities Used for Treatment-Resistant Depression in Adults , 2021, JAMA network open.

[3]  G. Kanevsky,et al.  Prevalence and Impact of Treatment-Resistant Depression in Latin America: a Prospective, Observational Study , 2021, Psychiatric Quarterly.

[4]  B. Mulsant,et al.  Targeting Metabolic Dysfunction for the Treatment of Mood Disorders: Review of the Evidence , 2021, Life.

[5]  P. Cowen,et al.  Statins in Depression: An Evidence-Based Overview of Mechanisms and Clinical Studies , 2021, Frontiers in Psychiatry.

[6]  B. Mulsant,et al.  Relationship between childhood trauma, personality, social support and depression in women attending general medical clinics in a low and middle-income country. , 2021, Journal of affective disorders.

[7]  P. Cowen,et al.  Statins for major depressive disorder: A systematic review and meta-analysis of randomized controlled trials , 2021, PloS one.

[8]  P. Lichtenstein,et al.  Associations between statin use and suicidality, depression, anxiety, and seizures: a Swedish total-population cohort study , 2020, The lancet. Psychiatry.

[9]  A. Young,et al.  Relative effectiveness of augmentation treatments for treatment-resistant depression: a systematic review and network meta-analysis , 2020, International review of psychiatry.

[10]  A. Young,et al.  Minocycline and celecoxib as adjunctive treatments for bipolar depression: a multicentre, factorial design randomised controlled trial. , 2020, The lancet. Psychiatry.

[11]  E. Binder,et al.  Dissecting the Association Between Inflammation, Metabolic Dysregulation, and Specific Depressive Symptoms , 2020, JAMA psychiatry.

[12]  O. Howes,et al.  Inflammatory markers in depression: A meta-analysis of mean differences and variability in 5,166 patients and 5,083 controls , 2020, Brain, Behavior, and Immunity.

[13]  B. Penninx,et al.  Depression Heterogeneity and Its Biological Underpinnings: Toward Immunometabolic Depression , 2020, Biological Psychiatry.

[14]  A. Mackinnon,et al.  Youth Depression Alleviation with Anti-inflammatory Agents (YoDA-A): a randomised clinical trial of rosuvastatin and aspirin , 2020, BMC Medicine.

[15]  C. Pariante,et al.  Markers of central inflammation in major depressive disorder: A systematic review and meta-analysis of studies examining cerebrospinal fluid, positron emission tomography and post-mortem brain tissue , 2019, Brain, Behavior, and Immunity.

[16]  S. Walters,et al.  Sample size estimation for randomised controlled trials with repeated assessment of patient-reported outcomes: what correlation between baseline and follow-up outcomes should we assume? , 2019, Trials.

[17]  A. Young,et al.  Adjunctive simvastatin for treatment-resistant depression: study protocol of a 12-week randomised controlled trial , 2019, BJPsych Open.

[18]  J. Ioannidis,et al.  Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis , 2018, The Lancet.

[19]  B. Penninx,et al.  Metabolic and inflammatory markers: associations with individual depressive symptoms , 2017, Psychological Medicine.

[20]  A. Young,et al.  Minocycline as an adjunct for treatment-resistant depressive symptoms: A pilot randomised placebo-controlled trial , 2017, Journal of psychopharmacology.

[21]  Siew Ching Ho,et al.  Barriers and facilitators of adherence to antidepressants among outpatients with major depressive disorder: A qualitative study , 2017, PloS one.

[22]  A. Carvalho,et al.  Peripheral cytokine and chemokine alterations in depression: a meta‐analysis of 82 studies , 2017, Acta psychiatrica Scandinavica.

[23]  B. Penninx.  Depression and cardiovascular disease: Epidemiological evidence on their linking mechanisms , 2017, Neuroscience & Biobehavioral Reviews.

[24]  J. Jakobsen,et al.  Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis , 2017, BMC Psychiatry.

[25]  S. Thuret,et al.  The Role of Lipid Biomarkers in Major Depression , 2017, Healthcare.

[26]  M. Berk,et al.  Statins for the treatment of depression: A meta-analysis of randomized, double-blind, placebo-controlled trials. , 2016, Journal of affective disorders.

[27]  Z. Baloch,et al.  Pathogenetic and Therapeutic Applications of Tumor Necrosis Factor-α (TNF-α) in Major Depressive Disorder: A Systematic Review , 2016, International journal of molecular sciences.

[28]  M. Izdebska,et al.  Estimation of oxidative stress parameters in rats after simultaneous administration of rosuvastatin with antidepressants , 2016, Pharmacological reports : PR.

[29]  Philippe Ravaud,et al.  Differential Globalization of Industry- and Non-Industry–Sponsored Clinical Trials , 2015, PloS one.

[30]  S. Akhondzadeh,et al.  Simvastatin as an adjuvant therapy to fluoxetine in patients with moderate to severe major depression: A double-blind placebo-controlled trial , 2015, Journal of psychopharmacology.

[31]  S. Brand,et al.  In a randomized, double-blind clinical trial, adjuvant atorvastatin improved symptoms of depression and blood lipid values in patients suffering from severe major depressive disorder. , 2014, Journal of psychiatric research.

[32]  Michael Berk,et al.  Oxidative & nitrosative stress in depression: Why so much stress? , 2014, Neuroscience & Biobehavioral Reviews.

[33]  B. Mulsant,et al.  A systematic approach to pharmacotherapy for geriatric major depression. , 2014, Clinics in geriatric medicine.

[34]  A. Rodrigues,et al.  Atorvastatin evokes a serotonergic system-dependent antidepressant-like effect in mice , 2014, Pharmacology Biochemistry and Behavior.

[35]  T. Rummans,et al.  Statins use and risk of depression: a systematic review and meta-analysis. , 2014, Journal of affective disorders.

[36]  A. Ghanizadeh,et al.  AUGMENTATION OF FLUOXETINE WITH LOVASTATIN FOR TREATING MAJOR DEPRESSIVE DISORDER, A RANDOMIZED DOUBLE‐BLIND PLACEBO CONTROLLED‐CLINICAL TRIAL , 2013, Depression and anxiety.

[37]  B. Nordestgaard,et al.  Elevated C-reactive protein levels, psychological distress, and depression in 73, 131 individuals. , 2013, JAMA psychiatry.

[38]  R. Ho,et al.  Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. , 2012, Journal of Affective Disorders.

[39]  C. Baldari,et al.  Opposite effects of simvastatin on the bactericidal and inflammatory response of macrophages to opsonized S. aureus , 2010, Journal of leukocyte biology.

[40]  M. Fava,et al.  Do atypical features affect outcome in depressed outpatients treated with citalopram? , 2010, The international journal of neuropsychopharmacology.

[41]  S. Kapur,et al.  The Maudsley Prescribing Guidelines , 2009 .

[42]  George F Borm,et al.  A simple sample size formula for analysis of covariance in randomized clinical trials. , 2007, Journal of clinical epidemiology.

[43]  S. Targum,et al.  The clinical global impressions scale: applying a research tool in clinical practice. , 2007, Psychiatry (Edgmont (Pa. : Township)).

[44]  Russell L. Kolts,et al.  Relationship Between Depression Severity Entry Criteria and Antidepressant Clinical Trial Outcomes , 2007, Biological Psychiatry.

[45]  A. Rush,et al.  The Montgomery Äsberg and the Hamilton ratings of depression: A comparison of measures , 2006, European Neuropsychopharmacology.

[46]  D. Kupfer,et al.  Acute and Longer- Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report , 2006 .

[47]  B. Löwe,et al.  A brief measure for assessing generalized anxiety disorder: the GAD-7. , 2006, Archives of internal medicine.

[48]  H. Bessler,et al.  Effect of pravastatin, simvastatin and atorvastatin on the phagocytic activity of mouse peritoneal macrophages. , 2006, Experimental and molecular pathology.

[49]  M. Schubert-Zsilavecz,et al.  Chronic Administration of Statins Alters Multiple Gene Expression Patterns in Mouse Cerebral Cortex , 2005, Journal of Pharmacology and Experimental Therapeutics.

[50]  J. Loike,et al.  Statin Inhibition of Fc Receptor–Mediated Phagocytosis by Macrophages Is Modulated by Cell Activation and Cholesterol , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[51]  U. Ahlfors,et al.  The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patients , 1987, Acta psychiatrica Scandinavica. Supplementum.

[52]  L. Green,et al.  Concurrent and Predictive Validity of a Self-reported Measure of Medication Adherence , 1986, Medical care.

[53]  M. Hamilton,et al.  Rating depressive patients. , 1980, The Journal of clinical psychiatry.

[54]  M. Åsberg,et al.  A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.

[55]  W. K. Simmons,et al.  Depression and obesity: evidence of shared biological mechanisms , 2018, Molecular Psychiatry.

[56]  J. Burgos,et al.  Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. , 2011, Journal of Alzheimer's disease : JAD.

[57]  Farooq Naeem,et al.  Psychologists experience of cognitive behaviour therapy in a developing country: a qualitative study from Pakistan , 2010, International journal of mental health systems.

[58]  H. Bessler,et al.  Hydrophobic but not hydrophilic statins enhance phagocytosis and decrease apoptosis of human peripheral blood cells in vitro. , 2008, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[59]  L. F. Junqueira,et al.  Effects of pravastatin on the in vitro phagocytic function and hydrogen peroxide production by monocytes of healthy individuals. , 2006, International immunopharmacology.

[60]  J. Fleiss.  Measuring nominal scale agreement among many raters. , 1971 .